Clinical trial of isophosphamide (NSC-109724)--results and side effects. 1974

D N Bremner, and J S McCormick, and J W Thomson

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003498 Cyclic P-Oxides Heterocyclic P-Oxides,Cyclic P Oxides,Heterocyclic P Oxides,Oxides, Cyclic P,P Oxides, Cyclic,P-Oxides, Cyclic,P-Oxides, Heterocyclic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003556 Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain. Cystitides

Related Publications

D N Bremner, and J S McCormick, and J W Thomson
January 1975, Cancer chemotherapy reports,
D N Bremner, and J S McCormick, and J W Thomson
April 1976, Cancer treatment reports,
D N Bremner, and J S McCormick, and J W Thomson
January 1974, Cancer chemotherapy reports,
D N Bremner, and J S McCormick, and J W Thomson
January 1974, Cancer chemotherapy reports,
D N Bremner, and J S McCormick, and J W Thomson
April 1976, Cancer treatment reports,
D N Bremner, and J S McCormick, and J W Thomson
December 1972, Cancer chemotherapy reports,
D N Bremner, and J S McCormick, and J W Thomson
October 1972, Cancer chemotherapy reports,
D N Bremner, and J S McCormick, and J W Thomson
March 1976, European journal of cancer,
Copied contents to your clipboard!